B-cell cancers

Iksuda Therapeutics Enters License Agreement With University of Goettingen to Develop a New Generation of Antibody Drug Conjugates

Newcastle, England:  Iksuda licenses novel protein-alkylating, tumour-activated pro-drug payload series to develop ADCs with enhanced therapeutic index Development to focus…

Read More »